Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 6/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521006 | 0.82 | KHK (0.58) | KHKNR3C1ALDH1A1HPGDHTT | |
| SCHEMBL4512852 | 0.80 | KHK (0.55) | KHKSMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL4501430 | 0.80 | USP2 (0.40) | KHKLMNASMN1; SMN2NR3C1L3MBTL1 | |
| SCHEMBL4500604 | 0.80 | KHK (0.48) | KHKLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4596672 | 0.79 | KHK (0.54) | KHKNR3C1ALDH1A1HPGDHTT | |
| SCHEMBL4521002 | 0.77 | TSHR (0.49) | NR3C1ALDH1A1HPGDTSHRNPSR1 | |
| SCHEMBL4507115 | 0.77 | KHK (0.63) | KHKLMNANR3C1ALDH1A1HPGD | |
| SCHEMBL4512848 | 0.75 | NPSR1 (0.42) | KHKSMN1; SMN2ALDH1A1POLBTSHR | |
| SCHEMBL4522989 | 0.75 | KHK (0.60) | KHKSMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL4511884 | 0.75 | KHK (0.54) | KHKALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | KHK 3420/4885PAX8 3017/4885LMNA 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.